eplontersen   Click here for help

GtoPdb Ligand ID: 13606

Synonyms: AKCEA-TTR-LRx | Ionis-TTR-LRx | Wainua® | Wainzua®
Approved drug
eplontersen is an approved drug (FDA (2023), EMA & UK MHRA (2024))
Compound class: Nucleic acid
Comment: Eplontersen is a ligand-conjugated transthyretin (TTR)-directed antisense oligonucleotide. It was designed to reduce the hepatic expression of transthyretin protein and pathological TTR amyloid accumulation in patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Full sequence as provided in the agent's INN record is: all-P-ambo-5'-O-(28-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acetamido-2-deoxy-β-D -galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy]methyl}- 1-hydroxy-1,10,14,21-tetraoxo-2,18-dioxa-9,15,22-triaza-1λ 5-phosphaoctacosan-1-yl)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2-methoxyethyl)guanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2- methoxyethyl)-5-methylcytidine, but we have been unable to resolve this to a SMILES or HELM notation.
References
1. Coelho T, Marques Jr W, Dasgupta NR, Chao CC, Parman Y, França Jr MC, Guo YC, Wixner J, Ro LS, Calandra CR et al.. (2023)
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
JAMA, 330 (15): 1448-1458. [PMID:37768671]
2. Coelho T, Waddington Cruz M, Chao CC, Parman Y, Wixner J, Weiler M, Barroso FA, Dasgupta NR, Jung SW, Schneider E et al.. (2023)
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Neurol Ther, 12 (1): 267-287. [PMID:36525140]